Vasoactive intestinal peptide analogs

Details Vasoactive intestinal peptide analogs Vasoactive intestinal peptide analogs

1988-01-21

1990-07-03

Lee, Lester L.

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

25 or more amino acid residues in defined sequence

C07K 710

Patent

active

049392247

ABSTRACT:
Novel, biologically active, 28-amino acid analogs of human vasoactive intestinal peptide are provided.

REFERENCES:
patent: 3880826 (1975-04-01), Said et al.
patent: 4016258 (1977-04-01), Said et al.
patent: 4119618 (1978-10-01), Said
patent: 4605641 (1986-08-01), Bolin et al.
patent: 4734400 (1988-03-01), Bolin et al.
patent: 4737487 (1988-04-01), Watts et al.
patent: 4757133 (1988-07-01), Ito et al.
patent: 4835252 (1989-05-01), Musso et al.
Musso, Ph.D. Dissertation, University of Chicago, Chicago, Ill., U.S.A. (3).
Robson et al., "Introduction to Proteins and Protein Engineering", Elsevier, Science publishers B. V. Amsterdam, New York, Oxford, pp. 323-325 (1986).
Beyerman et al., "Synthesis, Biological and Immunochemical Properties of Analogs of Secretin and Vasoactive Intestinal Peptide (VIP): The Vasectrins," Life Sciences 29, 895-802 (1981).
Takeyama et al., "Studies on Peptides. XCVII. Synthesis of Porcine Glu.sup.8 -Vasoactive Intestinal Polypeptide (VIP)," Chem. Pharm. Bull. 28(7), 2265-2269 (1980).
Bodansky and Natarajan, "Synthesis and Some Pharmacological Properties of the 23-Peptide 15-Lysine-Secretin-(5-27), Special Role of the Residue in Position 15 in Biological Activity of the Vasoactive Intestinal Polypeptide," Journal of Medicinal Chemistry 21, No. 11, 1171-1173 (1978).
Kaiser and Kezdy, "Amphiphilic Secondary Structure: Design of Peptide Hormones," Science 223, 249-255 (1984).
Robberecht et al., "Effects of HIS Modifications on the Ability of Vasoactive Intestinal Peptide to Stimulate Adenylate Cyclase from Rat and Human Tissues," Peptides 5, 877-881 (1984).
Turner et al., "A Fragment of Vasoactive Intestinal Peptide, VIP (10-28), is an Antagonist of VIP in the Colon Carcinoma Cell Line, HT29, " Peptides 7, 849-854 (1986).
James B. D. Palmer, et al., "VIP and PHM and their Role in Nonadrenergic Inhibitory Responses in Isolated Airways," Am. Physiol. Soc., pp. 1322-1328, 1986.
Patrick Robberecht et al., "[D-Phe.sup.4 ] Peptide Histidine-Isoleucinamide ([D-Phe.sup.4 ]PHI), a Highly Selective Vasoactive-Intestinal Peptide (VIP) Agonist, Discriminates VIP-Preferring from Secretin-Preferring Receptors in Rat Pancreatic Membranes," Eur. J. Biochem., 165: 243-249 (1987).
D. McMaster et al., "Iodinated Derivatives of Vasoactive Intestinal Peptide (VIP), PHI and PHM: Purification, Chemical Characterization and Biological Activity,.sbsp.qPeptides, vol. 8, pp. 663-676, 1987.
Alain Robichon et al., "Chemical Modification of Guanidinium Groups of Vasoactive Intestinal Peptide," Biochimica et. Biophysica Acta, vol. 923, pp. 250-256, 1987.
Dimaline et al., "A Novel Family of VIP-Like Peptides from the Dogfish Scyliorhinus Canicula," Reg. Peptides, 18: 356, 1987.
Dimaline et al., "The Novel Vasoactive Intestinal Peptide (VIP) from Elasmobranch Intestine has Full Affinity for Mammalian Pancreatic VIP Receptors," Biochim. Biophys. Acta 930, 97-100 (1987).

Affiliated with

Also associated with

Rating

Vasoactive intestinal peptide analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vasoactive intestinal peptide analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vasoactive intestinal peptide analogs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1891727